Bluejay Diagnostics Inc (BJDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bluejay Diagnostics Inc stock (BJDX) is currently trading at $1.96. Bluejay Diagnostics Inc PS ratio (Price-to-Sales) is 54.99. Analyst consensus price target for BJDX is $256.00. WallStSmart rates BJDX as Sell.
- BJDX PE ratio analysis and historical PE chart
- BJDX PS ratio (Price-to-Sales) history and trend
- BJDX intrinsic value — DCF, Graham Number, EPV models
- BJDX stock price prediction 2025 2026 2027 2028 2029 2030
- BJDX fair value vs current price
- BJDX insider transactions and insider buying
- Is BJDX undervalued or overvalued?
- Bluejay Diagnostics Inc financial analysis — revenue, earnings, cash flow
- BJDX Piotroski F-Score and Altman Z-Score
- BJDX analyst price target and Smart Rating
Bluejay Diagnostics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Bluejay Diagnostics Inc (BJDX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Bluejay Diagnostics Inc (BJDX) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Bluejay Diagnostics Inc (BJDX) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 55.0x annual revenue
Very low institutional interest at 4.07%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Bluejay Diagnostics Inc (BJDX) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.33) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (54.99) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -117.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -117.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BJDX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BJDX's Price-to-Sales ratio of 54.99x sits near its historical average of 54.99x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 54.99x set in Feb 2026, and 0% above its historical low of 54.99x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bluejay Diagnostics Inc (BJDX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Bluejay Diagnostics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.04 indicates a conservative balance sheet with 3M in cash.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Bluejay Diagnostics Inc.
Bottom Line
Bluejay Diagnostics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bluejay Diagnostics Inc(BJDX)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Bluejay Diagnostics Inc. is a pioneering medical technology company focused on enhancing patient outcomes through cutting-edge diagnostic solutions centered on early disease detection. Leveraging a proprietary technology platform that fuses artificial intelligence with point-of-care testing, Bluejay optimizes the precision and efficiency of diagnostic procedures, providing healthcare professionals with timely, actionable insights. As a leader in the diagnostic sector, the company is well-positioned to tackle critical gaps in healthcare delivery, underpinned by a strong commitment to research and development amid the growing demand for innovative, reliable diagnostic tools in a dynamic medical landscape.